Bona fide receptor for hepatitis B and D viral infections: Mechanism, research models and molecular drug targets

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
ritonavir 1 infectiousdiseasesdrugs
tenofovir 7 infectiousdiseasesdrugs
hepatitis B 10 infectiousdiseases
hepatitis C 2 infectiousdiseases
hepatitis D 1 infectiousdiseases

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
ritonavir 35808 demonstrating its low specificity. Other FDA-approved drugs, including cyclosporine B, propranolol, bosentan, ritonavir , and irbesartan, have also been verified as NTCP inhibitors for their potency in preventing HBV/HDV
tenofovir 1477 immunomodulator, as well as nucleos(t)ide analogs that have a high barrier to resistance, such as entecavir, tenofovir disoproxil or tenofovir alafenamide[2],[3]. However, these agents do not truly eradicate hepatitis
tenofovir 1502 nucleos(t)ide analogs that have a high barrier to resistance, such as entecavir, tenofovir disoproxil or tenofovir alafenamide[2],[3]. However, these agents do not truly eradicate hepatitis B virus (HBV) because covalently
tenofovir 29050 recent experiment involving 12 healthy volunteers assessed the coadministration of Myrcludex B with tenofovir , showing that Myrcludex B induced a remarkable increase in bile acid concentrations without causing
tenofovir 29206 increase in bile acid concentrations without causing any relevant symptoms and had no influence on tenofovir pharmacokinetics[76]. Currently, tenofovir, a nucleos(t)ide reverse transcriptase inhibitor, is a first-line
tenofovir 29249 without causing any relevant symptoms and had no influence on tenofovir pharmacokinetics[76]. Currently, tenofovir , a nucleos(t)ide reverse transcriptase inhibitor, is a first-line antiviral. The study indicated that
tenofovir 29408 is a first-line antiviral. The study indicated that Myrcludex B may provide an add-on treatment to tenofovir , but further research is still needed. Remarkably, Professor Heiner Wedemeyer, from Hannover Medical
tenofovir 29653 final results of a Phase 2b clinical trial (MYR 202), investigating a combination of Myrcludex B and tenofovir disoproxil fumarate (TDF) in chronic hepatitis B patients co-infected with HDV. The study recruited
Select Disease Character Offset Disease Term Instance
hepatitis B 60 Title: Emerging Microbes & InfectionsBona fide receptor for hepatitis B and D viral infections: Mechanism, research models and molecular drug targetsYueran YuShangda LiWeifeng
hepatitis B 601 polypeptide (NTCP), a liver-specific bile acid transporter, was identified as a bona fide receptor for hepatitis B virus (HBV) and its satellite virus, hepatitis delta virus (HDV). Identification of the HBV receptor
hepatitis B 979 discovered and describes its clinical significance as the receptor for HBV and HDV entry.IntroductionChronic hepatitis B (CHB) infection is a major public health problem that affects ~ 250 million people worldwide and can
hepatitis B 1577 tenofovir disoproxil or tenofovir alafenamide[2],[3]. However, these agents do not truly eradicate hepatitis B virus (HBV) because covalently closed circular DNA (cccDNA), which is associated with viral persistence,
hepatitis B 8990 that the S267F (c.800 C > T, rs2296651) NTCP variant is associated with resistance to chronic hepatitis B and a low incidence of acute-on-chronic liver failure[37]. Conversely, a smaller genetic association
hepatitis B 26142 proliferator-activated receptor gamma, TSH thyroid ttimulating hormone, VGLUT vesicular glutamate transporter, HBV hepatitis B virus, HDV hepatitis delta virus, PHH primary cultures of human hepatocyte, NTCP sodium taurocholate
hepatitis B 27424 clinical trial, the safety and tolerability of Myrcludex B were assessed. In one cohort, 40 chronic hepatitis B patients, who were HBeAg-negative (HBV DNA > 2000 IU/ml, median HBV DNA 4.7 log10 IU/ml, without
hepatitis B 28875 levels (Bogolomov et al., AASLD meeting 2014). Thus, Myrcludex B was safe and well tolerated in chronic hepatitis B patients with or without HDV coinfection. In addition, another recent experiment involving 12 healthy
hepatitis B 29701 202), investigating a combination of Myrcludex B and tenofovir disoproxil fumarate (TDF) in chronic hepatitis B patients co-infected with HDV. The study recruited 120 volunteers in 20 centers from Russia and Germany.
hepatitis B 37583 Notwithstanding, these novel agents require additional investigation and validation.ConclusionChronic hepatitis B infections are still a cause for concern owing to various uncontrollable complications. A number of
hepatitis C 16305 a high-affinity receptor for HBV and HDV, but it was also revealed as a host factor that regulates hepatitis C virus infection by augmenting the bile acid-mediated repression of interferon-stimulated genes[59].Identification
hepatitis C 17313 infection[18]. In 2002, the HepaRG cell line was obtained from a female suffering from liver cancer related to hepatitis C virus[19]. This cell line is a hepatic progenitor cell line possessing a bidirectional differentiation
hepatitis D 2225 extensions of the M and L proteins are referred to as preS2 and preS1/S2, respectively[5]. In contrast, hepatitis D virus (HDV), a satellite of HBV, makes use of HBV surface proteins for its packaging and cellular entry[6].

You must be authorized to submit a review.